Login to Your Account

Rhythm’s rare genetic obesity drug in first of two phase III studies

By Michael Fitzhugh
Staff Writer

Thursday, May 4, 2017

About three months after taking the wraps off a $41 million mezzanine financing, Rhythm Pharmaceuticals Inc. is kicking off a pivotal trial of its lead candidate, setmelanotide, for an ultra-rare genetic obesity disorder.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription